<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03718208</url>
  </required_header>
  <id_info>
    <org_study_id>Low calorie 001</org_study_id>
    <nct_id>NCT03718208</nct_id>
  </id_info>
  <brief_title>Acceptability and Tolerance Study of a Low Calorie Peptide Based Paediatric Tube Feed Formula.</brief_title>
  <official_title>To Evaluate the Acceptability (Including Gastro Intestinal Tolerance and Compliance) of a Low Calorie Peptide Based Paediatric Tube-feed Formula; for Children Greater Than 1 Year of Age.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an acceptability study to evaluate the gastrointestinal tolerance and compliance over&#xD;
      a seven-day period, of a low calorie paediatric peptide based tube feed formula for the&#xD;
      dietary management of participants with short bowel syndrome; intractable malabsorption;&#xD;
      preoperative preparation of undernourished patients; inflammatory bowel disease; total&#xD;
      gastrectomy; dysphagia; bowel fistulae;&#xD;
&#xD;
      The acceptability data from 15 participants will be collected in order to submit an&#xD;
      application to the Advisory Committee on Borderline Substances (ACBS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients well established and stable on a standard or peptide enteral tube feed will be&#xD;
      changed to a low calorie paediatric formula for a period of seven days. This group will act&#xD;
      as their own controls. Each child will receive for a period of seven days the paediatric&#xD;
      formula.&#xD;
&#xD;
      The dietitian will determine the feeding regimen on an individual basis and the enteral&#xD;
      formula will be provided via a feeding tube. A baseline questionnaire will be completed by&#xD;
      the dietitian to ensure eligibility of study, current stool patterns or symptoms and weight&#xD;
      at the start of the study.&#xD;
&#xD;
      The parents will complete a week intake chart to monitor how much feed has been consumed each&#xD;
      day and a tolerance diary to review gastrointestinal symptoms at the start and end of the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 8, 2018</start_date>
  <completion_date type="Actual">July 22, 2019</completion_date>
  <primary_completion_date type="Actual">July 22, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gastrointestinal tolerance</measure>
    <time_frame>Day 7 from baseline</time_frame>
    <description>Incidence of gastrointestinal adverse effects [ Time Frame: day 7 from baseline ].&#xD;
Tolerance will be evaluated on the basis of the number of gastrointestinal events including diarrhea, constipation, bloating, distension, nausea, vomiting, burping, flatulence and regurgitation and abdominal discomfort or pain reported for subjects during their participation in the study.&#xD;
nausea, vomiting. burping, flatulence and regurgitation and abdominal discomfort or pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant compliance</measure>
    <time_frame>Day 7 from baseline</time_frame>
    <description>Volume of test product prescribed versus actually taken</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body weight</measure>
    <time_frame>Day 7 from baseline</time_frame>
    <description>Weight will be measured in Kg</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Cerebral Palsy</condition>
  <arm_group>
    <arm_group_label>Paediatric formula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each child will receive for a period of seven days. The formula is a food for special medical purposes for use under medical supervision.&#xD;
The dietitian will determine the feeding regimen on an individual basis and the enteral formula will be provided via a feeding tube. One week intake diary, one week tolerance diary, product intake.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Paediatric Formula</intervention_name>
    <description>Children will switch over to the low calorie paediatric feed. Intake diaries and tolerance diaries will be completed for one week.</description>
    <arm_group_label>Paediatric formula</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Exclusively tube fed&#xD;
&#xD;
          -  Paediatrics aged 1 year above who require a low calorie feed&#xD;
&#xD;
          -  Children with Neurological impairment (NI) who require long term tube feeding&#xD;
&#xD;
          -  Patients established on a standard or peptide Enteral formula (no gastrointestinal&#xD;
             intolerances on a current formula)&#xD;
&#xD;
          -  Willingly given, written, informed consent from patient or parent/guardian.&#xD;
&#xD;
          -  Willingly given, written assent (if appropriate).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to comply with the study protocol, in the opinion of the investigator&#xD;
&#xD;
          -  Known food allergies to any ingredients (see ingredients list)&#xD;
&#xD;
          -  Patients with significant renal or hepatic impairment&#xD;
&#xD;
          -  Participation in another interventional study within 2 weeks of this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clare Thornton-Wood, BSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dietitian</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Waldron Health Centre</name>
      <address>
        <city>Amersham</city>
        <zip>SE14 6LD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alexandra Children's Hospital</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 5BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gorton Clinic</name>
      <address>
        <city>Manchester</city>
        <zip>M12 5JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>August 22, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>August 17, 2020</last_update_submitted>
  <last_update_submitted_qc>August 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebral Palsy</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Yes see details below</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The study has been published in a journal</ipd_time_frame>
    <ipd_access_criteria>Avaliable on the internet</ipd_access_criteria>
    <ipd_url>https://www.heraldopenaccess.us/openaccess/tolerance-and-acceptability-of-a-low-calorie-paediatric-peptide-enteral-tube-formula-a-multicentre-trial-in-the-united-kingdom</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

